bioRxivMicrobiology
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
Y. Watanabe, L. Mendonca, E. R. Allen, A. Howe, M. Lee, J. D. Allen, H. Chawla, D. Pulido, F. Donnellan, H. Davies, M. Ulaszewska, S. Belij-Rammerstorfer, S. Morris, A.-S. Krebs, W. Dejnirattisai, J. Mongkolsapaya, P. Supasa, G. R. Screaton, C. M. Green, T. Lambe, P. Zhang, S. C. Gilbert, M. Crispin
Abstract
Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
P. Zhang, S. Gilbert, … D. I. Stuart·bioRxiv·May 22, 2023
- Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform
C. Chevillard, A. Amen, … P. Fender·bioRxiv·Sep 13, 2021
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
W. Sun, S. R. Leist, … P. Palese·bioRxiv·Jul 26, 2020
- Molecular basis of Ad5-nCoV Vaccine-Induced Immunogenicity
Dongyang Dong, Yutong Song, … Sai Li·StructurePeer-reviewed·Mar 19, 2025
- Adenovirus-Vectored SARS-CoV-2 Vaccine Expressing S1-N Fusion Protein
M. S. Khan, E. Kim, … A. Gambotto·bioRxiv·May 9, 2022
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies.
A. J. Spencer, S. Morris, … T. Lambe·bioRxiv·Jun 8, 2021